

## **Adamis Pharmaceuticals Announces Investor Update Conference Call**

August 9, 2013 12:37 PM ET

SAN DIEGO, CA--(Marketwired - Aug 9, 2013) - Adamis Pharmaceuticals Corp. (OTCQB: ADMP) ("the Company"), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology, will host an investor conference call on Tuesday, August 13, 2013 at 4:15pm ET to provide a business update concerning the Company's recent corporate developments. The Company's President and CEO, Dr. Dennis Carlo, will host the call.

**Date: Tuesday, August 13, 2013**

**Time: 4:15pm ET (1:15pm PT)**

**US Dial-in (Toll-free): 1-855-327-6837**

**TOLL/International Dial-in: 1-778-327-3988**

**Reference: Adamis Pharmaceuticals Investor Update Conference Call**

A playback of the call will be available from 7:15pm ET on August 13, 2013 until 11:59 pm ET on August 20, 2013. To listen to the replay, call toll free 1-877-870-5176 within the United States or 1-858-384-5517 when calling internationally (toll). Please use the replay PIN number 105752.

### **About Adamis Pharmaceuticals Corporation**

Adamis Pharmaceuticals Corporation is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. Products in its specialty pharmaceutical pipeline include the Epinephrine Injection PFS syringe for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, a HFA inhaled nasal steroid product for the treatment of allergic rhinitis. Product candidates currently in development within its biotechnology pipeline include TeloB-VAX, a novel cell-based therapeutic cancer vaccine, and three drug product candidates, APC-100, APC-200, and APC-300, for the treatment of prostate cancer and inflammation.

### **Forward Looking Statements**

This press release may contain forward-looking statements that relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the ability to fund future product development and business operations; future revenues expected from any of the company's product candidates, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities; our ability to complete any future acquisitions of products, product candidates or technologies; and the intellectual property protection that may be afforded by any patents or patent applications relating to the company's technology. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis' filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC's web site at <http://www.sec.gov>. Except as required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.

**Related Links:** <http://adamispharmaceuticals.com/>

Contact:

**For Additional Information**

Mark Flather

Director, Investor Relations & Corporate Communications

Adamis Pharmaceuticals Corp.

Tel: 858- 412-7951

Email: [mflather@adamispharma.com](mailto:mflather@adamispharma.com)